Department of Neurology, Drum Tower Hospital of Nanjing Medical University, China.
CNS Neurosci Ther. 2013 Jan;19(1):48-52. doi: 10.1111/cns.12030. Epub 2012 Nov 20.
Few reports concerned on recombinant tissue plasminogen activator (rt-PA) treatment in stroke patients with decreased consciousness. This study assesses the efficacy and safety of intravenous rt-PA administration within 4.5 h in stroke patients with decreased consciousness.
A total of 136 stroke patients with decreased consciousness, who received or not rt-PA intravenously within 4.5 h after stroke onset from Jiangsu province of China from 2009 to 2012, were reviewed retrospectively. Glasgow Coma Scale (GCS), National Institute of Health Stroke Scale (NIHSS), intracranial hemorrhage rate, and mortality were used to determine patient outcome when discharged. A 3-month outcome was calculated by modified Rankin Scale (mRS) with score 0 to 1 considered favorable outcome.
Baseline characteristics of two groups were similar. When discharged, no significant differences were observed regarding NIHSS score (P = 0.994) or GCS score (P = 0.591) between groups. After 3 months, 22.8% patients in rt-PA group had favorable outcome as compared with 7.5% patients in control group (P = 0.014). Treatment with rt-PA did not significantly increase incidence of hemorrhage (P = 0.494) or mortality (P = 0.169).
Intravenous rt-PA administration within 4.5 h after onset of symptoms benefited stroke patients with abnormal consciousness.
很少有报道关注意识降低的脑卒中患者接受重组组织型纤溶酶原激活剂(rt-PA)治疗的情况。本研究评估了在脑卒中发病后 4.5 小时内给予静脉 rt-PA 治疗意识降低的脑卒中患者的疗效和安全性。
回顾性分析了 2009 年至 2012 年中国江苏省 136 例发病后 4.5 小时内接受或未接受静脉 rt-PA 治疗的意识降低的脑卒中患者。格拉斯哥昏迷量表(GCS)、美国国立卫生研究院卒中量表(NIHSS)、颅内出血率和死亡率用于判断出院时的患者结局。采用改良 Rankin 量表(mRS)评估 3 个月结局,评分 0-1 分认为结局良好。
两组患者的基线特征相似。出院时,两组 NIHSS 评分(P = 0.994)或 GCS 评分(P = 0.591)差异均无统计学意义。3 个月后,rt-PA 组 22.8%的患者结局良好,对照组为 7.5%(P = 0.014)。rt-PA 治疗并未显著增加出血(P = 0.494)或死亡率(P = 0.169)的发生率。
症状出现后 4.5 小时内给予静脉 rt-PA 治疗有益于意识异常的脑卒中患者。